Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.33
-4.3%
$0.28
$0.10
$0.49
$405.66M1.153.50 million shs2.62 million shs
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
$17.01
-3.4%
$18.32
$14.06
$27.29
$1.87B0.01639,792 shs807,213 shs
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$1.54
$1.55
$0.60
$4.69
$128.53M1.271.47 million shsN/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
$0.29
+2.1%
$0.31
$0.24
$3.31
$20.29M0.27471,131 shs472,293 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytoDyn Inc. stock logo
CYDY
CytoDyn
-4.32%-16.42%+41.01%+5.96%+36.05%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-3.41%-12.09%-2.91%-13.70%-9.62%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
+2.14%+0.55%-16.00%-45.81%-90.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.0451 of 5 stars
0.02.00.00.01.10.00.0
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
2.5779 of 5 stars
3.51.00.00.02.85.00.0
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
4.1771 of 5 stars
3.53.00.04.62.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.00
N/AN/AN/A
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
3.00
Buy$43.00152.79% Upside
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
0.00
N/AN/AN/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
3.00
Buy$2.78855.16% Upside

Current Analyst Ratings Breakdown

Latest CYDY, NAMS, OVID, and NGM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.00 ➝ $1.50
5/8/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $40.00
4/24/2025
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/8/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
3/24/2025
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
3/12/2025
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $3.00
3/3/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$41.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CytoDyn Inc. stock logo
CYDY
CytoDyn
$270K1,502.45N/AN/A($0.11) per share-2.96
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
$47.14M39.63N/AN/A$3.50 per share4.86
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$4.42M29.10N/AN/A$1.80 per share0.86
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
$548K37.81N/AN/A$1.24 per share0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CytoDyn Inc. stock logo
CYDY
CytoDyn
-$49.84M-$0.01N/AN/AN/AN/A-76.70%8/13/2025 (Estimated)
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-$176.94M-$1.88N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
-$52.34M-$0.35N/AN/AN/A-5,142.56%-39.24%-26.19%8/12/2025 (Estimated)

Latest CYDY, NAMS, OVID, and NGM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million
5/8/2025Q1 2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million
3/11/2025Q4 2024
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
-$0.16-$0.13+$0.03-$0.13$0.19 million$0.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/AN/AN/AN/AN/A
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A
0.35
0.35
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
N/A
10.61
10.61
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/A
7.79
7.79
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
0.18
5.66
5.66

Institutional Ownership

CompanyInstitutional Ownership
CytoDyn Inc. stock logo
CYDY
CytoDyn
5.06%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
89.89%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
75.74%
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
72.24%

Insider Ownership

CompanyInsider Ownership
CytoDyn Inc. stock logo
CYDY
CytoDyn
0.54%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
20.84%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
35.90%
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
13.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
CytoDyn Inc. stock logo
CYDY
CytoDyn
201.25 billion1.22 billionNot Optionable
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
4109.82 million74.37 millionOptionable
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
13883.46 million53.50 millionOptionable
Ovid Therapeutics Inc. stock logo
OVID
Ovid Therapeutics
6071.11 million61.57 millionOptionable

Recent News About These Companies

What is B. Riley's Estimate for OVID Q2 Earnings?
Wedbush Decreases Earnings Estimates for Ovid Therapeutics
Ovid Therapeutics (OVID) Receives a Buy from TD Cowen
Ovid Therapeutics price target lowered to $4 from $5 at BTIG
William Blair Sticks to Their Buy Rating for Ovid Therapeutics (OVID)
Ovid Therapeutics price target lowered to $3 from $4 at Wedbush

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CytoDyn stock logo

CytoDyn OTCMKTS:CYDY

$0.33 -0.01 (-4.32%)
As of 05/27/2025 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$17.01 -0.60 (-3.41%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$17.01 0.00 (0.00%)
As of 05/27/2025 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NGM Biopharmaceuticals stock logo

NGM Biopharmaceuticals NASDAQ:NGM

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$0.29 +0.01 (+2.14%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.29 0.00 (-0.14%)
As of 05/27/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.